

Golisano Children's Hospital Antibiotic Susceptibility Profile

(Data Collected 7/1/2023 - 6/30/2024)

Percent of Non-Duplicate Patient Isolates Susceptible to Achievable Serum Levels

Isolates from PICU and PCICU Patients (CH6N and CH6S)

| ORGANISM | No. of Non-Duplicate Isolates | Amikacin | Gentamicin | Tobramycin | Ampicillin | Ampicillin-Sulbactam | Amoxicillin-Clavulanate | Penicillin | Piperacillin-Tazobactam | Oxacillin | Meropenem | Ertapenem | Aztreonam | Cefazolin | Cefepime | Ceftriaxone | Vancomycin | Linezolid | Daptomycin | Erythromycin | Clindamycin | TMP-SMZ | Ciprofloxacin | Moxifloxacin | Nitrofurantoin ^a | Tetracycline | Minocycline | Tigecycline | |
|-------------------------------------|-------------------------------|----------|-----------------|------------|------------|----------------------|-------------------------|------------|-------------------------|-----------|-----------|-----------|-----------|-----------|----------|-------------|------------|-----------|------------|--------------|-------------|---------|---------------|--------------|-----------------------------|--------------|-------------|-------------|-----|
| <i>Escherichia coli</i> | 14 | 100 | 78 | 84 | 35 | | 100 | | 100 | | 100 | 100 | 85 | 84 | 85 | 85 | | | | | | | 78 | 76 | 100 | 100 | 85 | | |
| <i>Enterobacter cloacae</i> | 11 | 100 | 90 | 90 | 0 | 0 | 0 | | 63 | | 100 | 80 | 63 | 0 | 90 | 63 | | | | | | | 81 | 90 | 100 | | 81 | | 100 |
| <i>Pseudomonas aeruginosa</i> | 25 | 100 | | 96 | | | | | 91 | | 95 | | 95 | | 100 | | | | | | | | 100 | | | | | | |
| <i>Stenotrophomonas maltophilia</i> | 17 | | | | | | | | | | | | | | | | | | | | | 88 | | | | | | 100 | |
| <i>Staphylococcus aureus</i> | 35 | | 94 | | | | 71 | 28 | | 71 | | | | 71 | | | 100 | 100 | 100 | 47 | 60 | 100 | | 84 | | 88 | 100 | 100 | |
| <i>Enterococcus faecalis</i> | 15 | | 80 ^b | | 100 | | | 100 | | | | | | | | | 100 | 100 | 100 | | | | | | | | | | 100 |

^aSusceptible to levels achievable in urine only

^bSusceptible to high level gentamicin

Prepared Dwight J. Hardy, Ph.D.
 Director, Clinical Microbiology Labs
 UR Medicine Labs
 July 26, 2024